November 30, 2020 Open Accruing SARC Studies Open accruing studies for you to refer or enroll your patients: SARC024 for Rhabdomyosarcoma (alveolar and embryonal) and Mesenchymal Chondrosarcoma SARC031 for Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve … Read more
January 18, 2019 LILLY REPORTS RESULTS OF PHASE 3 SOFT TISSUE SARCOMA Today, Eli Lilly reported that the results of their Phase 3 study of olaratumab (LARTRUVO®) in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue … Read more
June 28, 2018 SARC Investigator-Initiated Osteosarcoma Study Shows Positive Results of Regorafenib SARC (Sarcoma Alliance for Research Through Collaboration) is pleased to report the positive results of their osteosarcoma trial of regorafenib. The goal of improving progression-free survival for patients receiving regorafenib … Read more
May 10, 2018 SARC009 PUBLISHED JAMA Oncology Publication of SARC Study of Dasatinib Under the leadership of Dr. Scott Schuetze, Professor at the Rogel Cancer Center, Michigan Medicine, the results of the collaborative trial of … Read more
June 22, 2017 SARC-SUPPORTED RESEARCH SHOWS PEMBROLIZUMAB A POTENTIALLY VIABLE TREATMENT FOR A SUBSET OF SARCOMAS SARC (Sarcoma Alliance for Research Through Collaboration) is pleased to report promising clinical trial results presented recently at ASCO 2017, the Annual Meeting of sarcoma cancer researchers. Melissa A. Burgess, … Read more
July 21, 2016 SARC RESEARCHERS REPORT IMMUNOTHERAPY EFFECTIVE IN SELECTED SARCOMA SUBTYPES PRELIMINARY RESULTS OF SARC028 In this first investigator-led study of pembrolizumab in multiple subtypes of sarcoma, researchers reported encouraging results at the recent ASCO (American Society of Clinical Oncology) meeting. … Read more